Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…Abstract Number: 607 • 2018 ACR/ARHP Annual Meeting
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055), a 12-month, global, Phase 3b/4 study, demonstrated that in…Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…Abstract Number: 609 • 2018 ACR/ARHP Annual Meeting
Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
Background/Purpose: Biologic DMARDs (bDMARDs) have proven efficacy in rheumatoid arthritis (RA) however, some patients inadequately response to multiple bDMARDs. This study aims to determine the…Abstract Number: 610 • 2018 ACR/ARHP Annual Meeting
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
Background/Purpose: Once sustained clinical remission is achieved under tratment with biological therapies, the most efficient strategy is optimization. Searching for the lowest effective dose for…Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…Abstract Number: 612 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab
Background/Purpose: A reduced clinical response in patients taking TNF-alpha inhibitors is influenced by their immunogenicity and therefore the importance of therapeutic drug monitoring has been…Abstract Number: 613 • 2018 ACR/ARHP Annual Meeting
Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study
Background/Purpose: To describe the baseline characteristics, patient and physician preferences of rheumatoid arthritis patients treated with biologics or targeted therapies in a real world setting.…Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…Abstract Number: 615 • 2018 ACR/ARHP Annual Meeting
The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing…Abstract Number: 616 • 2018 ACR/ARHP Annual Meeting
Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
Background/Purpose: Low dose weekly MTX remains the anchor drug for treatment of Rheumatoid Arthritis. The principal mechanism by which MTX suppresses inflammation in Rheumatoid Arthritis…Abstract Number: 617 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
Background/Purpose: Rituximab is an effective treatment for rheumatoid arthritis (RA). Data on long-term outcomes following rituximab treatment are limited. The aim of this study was…Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…Abstract Number: 619 • 2018 ACR/ARHP Annual Meeting
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
Background/Purpose: Evaluate the survival of the 2nd biological disease modifying drug (bDMARD)and to determine the causes of suspension of the 2nd bDMARD. Methods: Patients ≥…Abstract Number: 620 • 2018 ACR/ARHP Annual Meeting
Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)
Background/Purpose: The response rate of TNFis in RA is variable and to some extent unpredictable, making treatment decision-making quite complex. Some insurance carriers require RA…
ACR Meeting Abstracts